Muna Therapeutics vs NEOK Bio
Side-by-side comparison of AI visibility scores, market position, and capabilities
Muna Therapeutics raised $75M in 2024 targeting microglial biology in Alzheimer's disease, using iPSC-derived microglia models to identify novel drug targets that modulate brain immune function.
About
Muna Therapeutics focuses on microglial biology — the specialized immune cells of the brain — as the key to developing disease-modifying Alzheimer's therapies beyond amyloid targeting. The company uses induced pluripotent stem cell (iPSC)-derived microglia as disease models to identify and validate novel drug targets implicated by Alzheimer's genetics (TREM2, PLCG2, BIN1, APOE). This platform enables the company to study microglial dysfunction at scale and run drug screens against human-relevant cellular models.
NEOK Bio emerged from stealth in 2025 with $80M in funding targeting neuroinflammation pathways in Alzheimer's disease and ALS using a novel class of innate immune modulators.
About
NEOK Bio is targeting neuroinflammation — the chronic activation of brain immune cells (microglia and astrocytes) — as a primary driver of neurodegeneration in Alzheimer's disease, ALS, and Parkinson's disease. The company's small molecule drug candidates modulate the NLRP3 inflammasome and related innate immune pathways in the brain, aiming to reduce the toxic inflammatory environment that kills neurons over time.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Muna Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.